The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells

Nature Methods

Volumn 11, Issue 5, 2014, Pages 585-592

  Petschnigg, Julia ^a   Groisman, Bella ^a   Kotlyar, Max ^b   Taipale, Mikko ^c   Zheng, Yong ^d   Kurat, Christoph F ^a,h   Sayad, Azin ^a   Sierra, J Rafael ^b   Usaj, Mojca Mattiazzi ^a   Snider, Jamie ^a   Nachman, Alex ^a   Krykbaeva, Irina ^c   Tsao, Ming Sound ^a,b   Moffat, Jason ^a   Pawson, Tony ^d   Lindquist, Susan ^c,e,f   Jurisica, Igor ^a,b,g   Stagljar, Igor ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAMMALIAN MEMBRANE TWO HYBRID ASSAY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SIGNAL TRANSDUCTION; STIMULUS; TWO HYBRID SYSTEM; WESTERN BLOTTING;

MAMMALIA;

CARCINOMA, NON-SMALL-CELL LUNG; CELL MEMBRANE; CELL SURVIVAL; CYTOSOL; HEK293 CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MUTATION; PHOSPHORYLATION; PHOSPHOTYROSINE; PLASMIDS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSCRIPTION FACTORS; TWO-HYBRID SYSTEM TECHNIQUES; UBIQUITIN;

EID: 84899903279     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.2895     Document Type: Article

References (49)

1. Stevens, T.J. & Arkin, I.T. Do more complex organisms have a greater proportion of membrane proteins in their genomes? Proteins 39, 417-420 (2000).
2. Jones, R.B., Gordus, A., Krall, J.A. & MacBeath, G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174 (2006).
3. Schulze, W.X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 2005.0008 (2005).
4. Lievens, S., Lemmens, I. & Tavernier, J. Mammalian two-hybrids come of age. Trends Biochem. Sci. 34, 579-588 (2009).
5. Michnick, S.W., Ear, P.H., Manderson, E.N., Remy, I. & Stefan, E. Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat. Rev. Drug Discov. 6, 569-582 (2007).
6. Rojo-Niersbach, E., Morley, D., Heck, S. & Lehming, N. A new method for the selection of protein interactions in mammalian cells. Biochem. J. 348, 585-590 (2000).
7. Kerppola, T.K. Visualization of molecular interactions by fluorescence complementation. Nat. Rev. Mol. Cell Biol. 7, 449-456 (2006).
8. Stefan, E. et al. Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. Proc. Natl. Acad. Sci. USA 104, 16916-16921 (2007).
9. Wehrman, T.S. et al. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc. Natl. Acad. Sci. USA 103, 19063-19068 (2006).
10. Wehr, M.C. et al. Monitoring regulated protein-protein interactions using split TEV. Nat. Methods 3, 985-993 (2006).
11. Ciruela, F. Fluorescence-based methods in the study of protein-protein interactions in living cells. Curr. Opin. Biotechnol. 19, 338-343 (2008).
12. Johnsson, N. & Varshavsky, A. Split ubiquitin as a sensor of protein interactions in vivo. Proc. Natl. Acad. Sci. USA 91, 10340-10344 (1994).
13. Stagljar, I., Korostensky, C., Johnsson, N. & te Heesen, S. A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. Proc. Natl. Acad. Sci. USA 95, 5187-5192 (1998).
14. Paumi, C.M. et al. Mapping protein-protein interactions for the yeast ABC transporter Ycf1p by integrated split-ubiquitin membrane yeast two-hybrid analysis. Mol. Cell 26, 15-25 (2007).
15. Snider, J. et al. Mapping the functional yeast ABC transporter interactome. Nat. Chem. Biol. 9, 565-572 (2013).
16. Emami, K.H. & Carey, M. A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. EMBO J. 11, 5005-5012 (1992).
17. Sadowski, I., Ma, J., Triezenberg, S. & Ptashne, M. GAL4-VP16 is an unusually potent transcriptional activator. Nature 335, 563-564 (1988).
18. Schmitz, M.L. & Baeuerle, P.A. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J. 10, 3805-3817 (1991).
19. Remy, I. & Michnick, S.W. Application of protein-fragment complementation assays in cell biology. Biotechniques 42, 137-141 (2007).
20. Johnsson, N. & Varshavsky, A. Ubiquitin-assisted dissection of protein transport across membranes. EMBO J. 13, 2686-2698 (1994).
21. Rhee, Y., Gurel, F., Gafni, Y., Dingwall, C. & Citovsky, V. A genetic system for detection of protein nuclear import and export. Nat. Biotechnol. 18, 433-437 (2000).
22. Deribe, Y.L. et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal. 2, ra84 (2009).
23. Moore, C.A., Milano, S.K. & Benovic, J.L. Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 69, 451-482 (2007).
24. DeWire, S.M., Ahn, S., Lefkowitz, R.J. & Shenoy, S.K. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510 (2007).
25. Yarden, Y. & Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001).
26. Prickett, T.D. et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132 (2009).
27. da Cunha Santos, G., Shepherd, F.A. & Tsao, M.S. EGFR mutations and lung cancer. Annu. Rev. Pathol. 6, 49-69 (2011).
28. Pines, G., Kostler, W.J. & Yarden, Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 584, 2699-2706 (2010).
29. Carey, K.D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171 (2006).
30. Shortt, J. & Johnstone, R.W. Oncogenes in cell survival and cell death. Cold Spring Harb. Perspect. Biol. 4, a009829 (2012).
31. Ahn, R. et al. The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression. Cancer Res. 73, 4521-4532 (2013).
32. Bisson, N. et al. Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor. Nat. Biotechnol. 29, 653-658 (2011).
33. Barrios-Rodiles, M. et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621-1625 (2005).
34. Taipale, M. et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150, 987-1001 (2012).
35. Blakely, K., Ketela, T. & Moffat, J. Pooled lentiviral shRNA screening for functional genomics in mammalian cells. Methods Mol. Biol. 781, 161-182 (2011).
36. Sriram, G. & Birge, R.B. Emerging roles for crk in human cancer. Genes Cancer 1, 1132-1139 (2010).
37. Cheung, H.W. et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 1, 608-625 (2011).
38. Kosaka, T., Yamaki, E., Mogi, A. & Kuwano, H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J. Biomed. Biotechnol. 2011, 165214 (2011).
39. Li, J. et al. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol. Syst. Biol. 9, 705 (2013).
40. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 8, 659-661 (2011).
41. Lemercier, C. et al. mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. J. Biol. Chem. 275, 15594-15599 (2000).
42. Kurat, C.F. et al. Restriction of histone gene transcription to S phase by phosphorylation of a chromatin boundary protein. Genes Dev. 25, 2489-2501 (2011).
43. Brown, K.R. & Jurisica, I. Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biol. 8, R95 (2007).
44. Zhu, C.Q. et al. Understanding prognostic gene expression signatures in lung cancer. Clin. Lung Cancer 10, 331-340 (2009).
45. Marcotte, R. et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2, 172-189 (2012).
46. Pinheiro, J.C. & Bates, D.M. Mixed-effects models in S and S-PLUS (Springer, 2000).
47. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
48. Chung, Y., Rabe-Hesketh, S., Dorie, V., Gelman, A. & Liu, J. A nondegenerate penalized likelihood estimator for variance parameters in multilevel models. Psychometrika 78, 685-709 (2013).
49. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).